October 01, 2020 Gout flop leaves Sobi red-faced SEL-212 fails to beat Krystexxa in phase II, but why did Sobi pay $100m for the asset in June and then put it into phase III?
June 26, 2020 Rare diseases dominate catalysts for the smallest companies Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
February 13, 2019 Another knock back for urea cycle disorders Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.